• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

在B细胞淋巴瘤模型中,CD4+CD25+调节性T细胞在肿瘤发展的早期而非晚期主导多种免疫逃逸机制。

CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model.

作者信息

Elpek Kutlu G, Lacelle Chantale, Singh Narendra P, Yolcu Esma S, Shirwan Haval

机构信息

Institute for Cellular Therapeutics and Department of Microbiology and Immunology, University of Louisville, Louisville, KY 40202, USA.

出版信息

J Immunol. 2007 Jun 1;178(11):6840-8. doi: 10.4049/jimmunol.178.11.6840.

DOI:10.4049/jimmunol.178.11.6840
PMID:17513732
Abstract

Tumors use a complex set of direct and indirect mechanisms to evade the immune system. Naturally arising CD4(+)CD25(+)FoxP3(+) T regulatory (Treg) cells have been implicated recently in tumor immune escape mechanism, but the relative contribution of these cells to overall tumor progression compared with other immune evasion mechanisms remains to be elucidated. Using the A20 B cell lymphoma as a transplantable tumor model, we demonstrate that this tumor employs multiple direct (expression of immunoinhibitory molecule PD-L1, IDO, and IL-10, and lack of expression of CD80 costimulatory molecule) and indirect (down-regulation of APC function and induction of Treg cells) immune evasion mechanisms. Importantly, Treg cells served as the dominant immune escape mechanism early in tumor progression because the physical elimination of these cells before tumor challenge resulted in tumor-free survival in 70% of mice, whereas their depletion in animals with established tumors had no therapeutic effect. Therefore, our data suggest that Treg cells may serve as an important therapeutic target for patients with early stages of cancer and that more vigorous combinatorial approaches simultaneously targeting multiple immune evasion as well as immunosurveillance mechanisms for the generation of a productive immune response against tumor may be required for effective immunotherapy in patients with advanced disease.

摘要

肿瘤利用一系列复杂的直接和间接机制来逃避免疫系统。天然产生的CD4(+)CD25(+)FoxP3(+)调节性T(Treg)细胞最近被认为参与了肿瘤免疫逃逸机制,但与其他免疫逃逸机制相比,这些细胞对肿瘤整体进展的相对贡献仍有待阐明。利用A20 B细胞淋巴瘤作为可移植肿瘤模型,我们证明该肿瘤采用了多种直接(免疫抑制分子PD-L1、IDO和IL-10的表达,以及共刺激分子CD80的缺乏表达)和间接(抗原呈递细胞功能下调和Treg细胞诱导)免疫逃逸机制。重要的是,Treg细胞在肿瘤进展早期作为主要的免疫逃逸机制,因为在肿瘤攻击前物理清除这些细胞导致70%的小鼠无瘤存活,而在已建立肿瘤的动物中耗尽这些细胞则没有治疗效果。因此,我们的数据表明,Treg细胞可能是癌症早期患者的重要治疗靶点,对于晚期疾病患者的有效免疫治疗,可能需要更有力的联合方法,同时针对多种免疫逃逸以及免疫监视机制,以产生针对肿瘤的有效免疫反应。

相似文献

1
CD4+CD25+ T regulatory cells dominate multiple immune evasion mechanisms in early but not late phases of tumor development in a B cell lymphoma model.在B细胞淋巴瘤模型中,CD4+CD25+调节性T细胞在肿瘤发展的早期而非晚期主导多种免疫逃逸机制。
J Immunol. 2007 Jun 1;178(11):6840-8. doi: 10.4049/jimmunol.178.11.6840.
2
T regulatory cells control T-cell proliferation partly by the release of soluble CD25 in patients with B-cell malignancies.调节性 T 细胞通过释放可溶性 CD25 来部分控制 B 细胞恶性肿瘤患者 T 细胞的增殖。
Immunology. 2010 Nov;131(3):371-6. doi: 10.1111/j.1365-2567.2010.03308.x.
3
Role of STAT3 in CD4+CD25+FOXP3+ regulatory lymphocyte generation: implications in graft-versus-host disease and antitumor immunity.信号转导与转录激活因子3(STAT3)在CD4+CD25+FOXP3+调节性淋巴细胞生成中的作用:对移植物抗宿主病和抗肿瘤免疫的影响
J Immunol. 2007 Dec 1;179(11):7593-604. doi: 10.4049/jimmunol.179.11.7593.
4
Acute Myeloid Leukemia Cells Express ICOS Ligand to Promote the Expansion of Regulatory T Cells.急性髓系白血病细胞表达 ICOSL 配体促进调节性 T 细胞的扩增。
Front Immunol. 2018 Sep 26;9:2227. doi: 10.3389/fimmu.2018.02227. eCollection 2018.
5
Cyclic adenosine monophosphate involvement in low-dose cyclophosphamide-reversed immune evasion in a mouse lymphoma model.环磷酸腺苷参与低剂量环磷酰胺逆转小鼠淋巴瘤模型中的免疫逃逸。
Cell Mol Immunol. 2012 Nov;9(6):482-8. doi: 10.1038/cmi.2012.34. Epub 2012 Sep 24.
6
Ex vivo expansion of CD4+CD25+FoxP3+ T regulatory cells based on synergy between IL-2 and 4-1BB signaling.基于白细胞介素-2与4-1BB信号协同作用的CD4+CD25+FoxP3+调节性T细胞的体外扩增
J Immunol. 2007 Dec 1;179(11):7295-304. doi: 10.4049/jimmunol.179.11.7295.
7
Regulatory T cells are necessary for implantation and maintenance of early pregnancy but not late pregnancy in allogeneic mice.调节性 T 细胞对于同种异体小鼠的早期妊娠着床和维持是必要的,但对于晚期妊娠则不是必需的。
J Reprod Immunol. 2010 Jun;85(2):121-9. doi: 10.1016/j.jri.2010.02.006. Epub 2010 May 2.
8
CD69+ CD4+ CD25- T cells, a new subset of regulatory T cells, suppress T cell proliferation through membrane-bound TGF-beta 1.CD69+ CD4+ CD25- T细胞是调节性T细胞的一个新亚群,通过膜结合型转化生长因子β1抑制T细胞增殖。
J Immunol. 2009 Jan 1;182(1):111-20. doi: 10.4049/jimmunol.182.1.111.
9
Targeted inhibition of IL-10-secreting CD25- Treg via p38 MAPK suppression in cancer immunotherapy.通过抑制 p38 MAPK 抑制肿瘤免疫治疗中 IL-10 分泌的 CD25-Treg
Eur J Immunol. 2010 Apr;40(4):1011-21. doi: 10.1002/eji.200939513.
10
Functional role of regulatory T cells in B cell lymphoma and related mechanisms.调节性T细胞在B细胞淋巴瘤中的功能作用及相关机制
Int J Clin Exp Pathol. 2015 Aug 1;8(8):9133-9. eCollection 2015.

引用本文的文献

1
A temporal model of tumor-immune dynamics during the metastatic progression of high-grade serous ovarian cancer.高级别浆液性卵巢癌转移进展过程中肿瘤-免疫动力学的时间模型。
NPJ Precis Oncol. 2025 Jun 16;9(1):188. doi: 10.1038/s41698-025-00973-y.
2
Using major histocompatibility complex (MHC) II expression to predict antitumor response to CD4 + lymphocyte depletion.利用主要组织相容性复合体(MHC)II类表达预测对CD4 +淋巴细胞耗竭的抗肿瘤反应。
Sci Rep. 2025 Feb 14;15(1):5469. doi: 10.1038/s41598-025-88972-8.
3
Transcriptomic classification of diffuse large B-cell lymphoma identifies a high-risk activated B-cell-like subpopulation with targetable MYC dysregulation.
弥漫性大B细胞淋巴瘤的转录组分类鉴定出一个具有可靶向的MYC失调的高危活化B细胞样亚群。
Nat Commun. 2024 Aug 8;15(1):6790. doi: 10.1038/s41467-024-50830-y.
4
Inhibition of SRC-3 as a potential therapeutic strategy for aggressive mantle cell lymphoma.抑制 SRC-3 作为侵袭性套细胞淋巴瘤的一种潜在治疗策略。
PLoS One. 2024 Apr 29;19(4):e0289902. doi: 10.1371/journal.pone.0289902. eCollection 2024.
5
A Hepatitis B Virus Reactivation Case Potentially Triggered by the Onset of Diffuse Large B Cell Lymphoma.乙型肝炎病毒再激活病例可能由弥漫性大 B 细胞淋巴瘤的发病引发。
Intern Med. 2023 Jun 1;62(11):1611-1615. doi: 10.2169/internalmedicine.0420-22. Epub 2022 Oct 19.
6
Regulatory T Cell Depletion Using a CRISPR Fc-Optimized CD25 Antibody.使用 CRISPR Fc 优化的 CD25 抗体耗竭调节性 T 细胞。
Int J Mol Sci. 2022 Aug 5;23(15):8707. doi: 10.3390/ijms23158707.
7
FcγRIIB controls antibody-mediated target cell depletion by ITIM-independent mechanisms.FcγRIIB 通过非 ITIM 依赖的机制控制抗体介导的靶细胞耗竭。
Cell Rep. 2022 Jul 19;40(3):111099. doi: 10.1016/j.celrep.2022.111099.
8
Factors related to the suppression of the antitumour immune response in female dogs with inflammatory mammary carcinoma.与雌性患有炎性乳腺癌的犬抗肿瘤免疫反应抑制相关的因素。
PLoS One. 2022 May 5;17(5):e0267648. doi: 10.1371/journal.pone.0267648. eCollection 2022.
9
Epigenetic, Metabolic, and Immune Crosstalk in Germinal-Center-Derived B-Cell Lymphomas: Unveiling New Vulnerabilities for Rational Combination Therapies.生发中心来源的B细胞淋巴瘤中的表观遗传、代谢和免疫串扰:揭示合理联合治疗的新弱点
Front Cell Dev Biol. 2022 Jan 7;9:805195. doi: 10.3389/fcell.2021.805195. eCollection 2021.
10
Two novel human anti-CD25 antibodies with antitumor activity inversely related to their affinity and in vitro activity.两种新型人源抗 CD25 抗体具有抗肿瘤活性,其亲和力和体外活性呈负相关。
Sci Rep. 2021 Nov 25;11(1):22966. doi: 10.1038/s41598-021-02449-y.